NCT06851962 - Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial | Biotech Hunter

Enrollment

504

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Metformin

Metformin maximum daily dose 2000 mg

DRUG

Dulaglutide

DRUG

Semaglutide 1.0 mg

Semaglutide

DRUG

Empagliflozin (BI 10773)

Empagliflozin

DRUG

Canagliflozin

DRUG

Dapagliflozin

DRUG

pioglitazone

Pioglitazone

DRUG

Sitagliptin

DRUG

Vildagliptin (Galvus)

vildagliptin

DRUG

linagliptin

Trial Locations (4)

29010

Hospital Universitario Regional de Málaga, Málaga

46010

Hospital Clínico Universitario de Valencia, Valencia

46014

Hospital General Universitario de Valencia (HGUV), Valencia

47012

Hospital Universitario Rio Hortega de Valladolid (HURH), Valladolid

All Listed Sponsors

lead

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER